Hematology

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

Vitamin C Enhances Epigenetic Treatments in Acute Myeloid Leukemia and Myeloid Dysplastic Syndrome

By

Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.

Costs, Hospital Stays for BSIs Significant in Pediatric Oncology Outpatient Setting

By

Ambulatory bloodstream infections in pediatric oncology and stem cell transplant patients result in significant health care charges and extended hospital admissions.

Bone Marrow vs Bloodstream: Stem Cell Source Influences Transplantation Outcomes

Bone Marrow vs Bloodstream: Stem Cell Source Influences Transplantation Outcomes

By

Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.

Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma

Gene Expression Alters Bone Marrow Environment in MGUS, Leading to Multiple Myeloma

By

Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.

Dose of Transplanted Blood-Forming Bone Marrow Cells Affects How Transplanted Cells Act

Dose of Transplanted Blood-Forming Bone Marrow Cells Affects How Transplanted Cells Act

By

Bone marrow transplantation can be improved by optimizing the dose of transplanted hematopoietic stem cells, according to recent results from a mouse model.

Frailty Is a Concerning Factor Among Young Bone Marrow Transplant Survivors

Frailty Is a Concerning Factor Among Young Bone Marrow Transplant Survivors

By

Incidence of frailty among young survivors of bone marrow transplant is similar to that of the elderly population, and increases the risk of death compared with nonfrail survivors.

Risk-specific Prevention Strategies Effectively Reduce Falls on Malignant Hematology Unit

Risk-specific Prevention Strategies Effectively Reduce Falls on Malignant Hematology Unit

By

High-risk medications can increase falls in patients undergoing treatment for malignant hematology, but implementing risk-specific fall prevention strategies can ameliorate the effects of the drugs.

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

By

Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.

Bone Pain Due to White Blood Cell Growth Factors

Bone Pain Due to White Blood Cell Growth Factors

By

How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?

Expected PCO2 (Winters)

A calculator for determining Expected PCO2 (Winters).

Survey Shows Clinician Opinions on Timing of End-of-life Discussions for Patients With Blood Cancers

By

In a survey on end-of-life (EOL) discussions, hematologic oncologists reported that these discussions with patients who have blood cancers occur too late, according to a recent report.

High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With Amyloidosis

By

Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.

Proactive telephone support reduces unplanned hospitalizations in blood cancers

Proactive telephone support reduces unplanned hospitalizations in blood cancers

By

Implementing proactive telephone support reduced unplanned hospitalizations among patients with blood cancers by 70%.

Genetically engineered immunotoxin shows early promise for B-cell malignancies

By

DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be effective in a small group of patients with relapsed/refractory B-cell malignancies, according to clinical trial results.

Epigenetic therapy clinically active against several blood cancers

Epigenetic therapy clinically active against several blood cancers

By

Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.

CAR cell engineering offers hope for patients with hard-to-treat blood disorders

By

The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.

TRAIL stops graft-vs-host disease after stem cell transplant for leukemia

T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.

Therapy-related leukemia risk varied from 1975 to 2008

Therapy-related leukemia risk varied from 1975 to 2008

The risk of developing therapy-related acute myeloid leukemia after chemotherapy varies depending on initial cancer and treatment practices.

Best leukemia therapy may depend on patient age

By

Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.

Pomalidomide extends survival in multiple myeloma

A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.

Study drug makes marrow transplant possible in relapsed leukemia

The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.

December 2012 Briefing - Hematology & Oncology

A round-up of some of the top developments in hematology and oncology in December 2012.

Ibrutinib appears safe, effective against chronic lymphocytic leukemia

Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.

Anticancer agent reduces complications after stem-cell transplant

Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.

ONS Connections: Reliable biomarker for central nervous system tissue injury during pediatric leukemia treatment

By

During the post-induction phase of treatment for childhood acute lymphoblastic leukemia (ALL), F2 isoprostanes significantly increase, allowing central nervous system (CNS) tissue injury to be monitored.

Higher rates of chronic GVHD seen with peripheral blood stem cell transplants from unrelated donors

By

Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).

New tool determines "readiness to die" of leukemia cells

By

A novel method has been developed to determine how ready acute myeloid leukemia (AML) cells are to die. This discovery may help to more effectively choose treatment options for patient with AML.

Children with acute myeloid leukemia benefit from improved diagnostic test

By

Flow cytometry has been identified as better for checking for minimal residual disease than two other widely used methods to predict patient survival.

August 2012 Briefing - Hematology & Oncology

A roundup of the top hematology and oncology news in August 2012.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs